



May 22, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub: Investor Presentation

**Ref: HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/
BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held on this day, 22nd May 2018, *inter alia*, has approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2018.

In this respect, we enclose herewith the Presentation on the Financial Results for the quarter and year ended March 31, 2018.

Request you to take this on record.

For HealthCare Global Enterprises Limited

SUNU MANUEL Digitally signed by SUNU
MANUEL
Date: 2018.05.22 15:53:55 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above



adding life to years

May 22, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub: Investor Presentation

**Ref: HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/
BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held on this day, 22nd May 2018, *inter alia*, has approved the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2018.

In this respect, we enclose herewith the Presentation on the Financial Results for the quarter and year ended March 31, 2018.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above

HealthCare Global Enterprises Ltd.

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489


Ahmedabad | Bangalore | Baroda | Chennai | Cuttack | Delhi | Erode | Hassan | Hubli | Kanpur | Kochi | Mangalore | Mumbai | Mysore | Nasik | Ongole | Ranchi | Shimoga | Trichy | Uganda | Vijayawada | Vizag



HealthCare Global Enterprises Limited

Q4-FY18 and FY18 : Investor Presentation

May 2018



Disclaimer



THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This presentation has been prepared by HealthCare Global Enterprises Limited (the "**Company**"). These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.


No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

Table of Contents





Financial Highlights: Q4 and FY18



INR million except earnings per share

Period Ended March 31	Q4-FY18	Q4-FY17	Growth (y-o-y)	FY18	FY17	Growth (y-o-y)
Income from Operations	2,223	1,824	21.8%	8,307	7,001	18.7%
Other Income	26	36		128	97	
EBITDA⁽¹⁾	348	336	3.7%	1,316	1,147	14.8%
EBITDA Margin (%)	15.5%	18.0%		15.6%	16.2%	
Operating EBITDA⁽²⁾	322	300	7.4%	1,188	1,050	13.2%
EBITDA Margin (%)	14.5%	16.4%		14.3%	15.0%	
PBT⁽³⁾	21	117	-81.7%	272	348	-22.0%
PBT Margin (%)	1.0%	6.4%		3.3%	5.0%	
PAT⁽⁴⁾	26	69	-62.5%	205	222	-7.4%
PAT Margin (%)	1.2%	3.8%		2.5%	3.2%	
Earnings Per Share	0.31	0.90	-65.6%	2.40	2.69	-10.8%

1) Profit before depreciation/amortization, finance costs, exceptional items and taxes

2) EBITDA excluding other Income

3) Profit before tax and exceptional items

4) Profit for the period after taxes and minority interests

- Q4'18 Revenue grew 21.8% y-o-y
 - HCG⁽¹⁾ centers: +23.2%
 - Milann⁽²⁾ centers: +8.0%
- Q4'18 Operating EBITDA increased 7.4% y-o-y
 - Existing centers: INR 343 Mn (19.6% margin vs 19.3% margin in Q4-FY17)
 - New centers⁽³⁾: Loss of INR -21 Mn (vs. loss of INR -9 Mn in Q4-FY17)
- FY18 Revenue grew 18.7% y-o-y
 - HCG⁽¹⁾ centers: +19.1%
 - Milann⁽²⁾ centers: +13.5%
- FY18 Operating EBITDA increased 13.2% y-o-y
 - Existing centers: INR 1278 Mn (18.7% margin vs 17.6% margin in FY17)
 - New centers⁽³⁾: Loss of INR -90 Mn (vs. INR -69 Mn in FY17)

(1) 19 comprehensive cancer centers (including center in Kenya), 2 multispecialty hospitals, 3 diagnostic centers and 1 day care chemotherapy center operated under "HCG" brand and 1 multispecialty hospital managed by HCG.

(2) 8 fertility centers operated under "Milann" brand

(3) 7* HCG centers and 5 Milann centers that commenced operation after April 1, 2015


*Financials of HCG center in Kenya & Strand Life Science consolidated at equity level



Revenue Mix: FY18




Revenue:
INR 8,307 Mn



(1) 19 comprehensive cancer centers (including center in Kenya), 2 multispecialty hospitals, 3 diagnostic centers and 1 day care chemotherapy center operated under “HCG” brand and 1 multispecialty hospital managed by HCG, as at March 31 2018

(2) 8 fertility centers operated under “Milann” brand

HCG Centers:
INR 7,638 Mn



¹(FY17)



HCG Centers: Q4 and FY18 Revenues



INR million

Period Ended March 31	Q4-FY18	Q4-FY17	Growth (y-o-y)	FY18	FY17	Growth (y-o-y)
Karnataka	835	725	15.2%	3,247	2,899	12.0%
Gujarat	588	514	14.3%	2,220	1,855	19.7%
Maharashtra	228	77	198.0%	672	244	175.0%
East India	148	126	17.4%	587	491	19.5%
Andhra Pradesh	144	110	30.4%	497	375	32.7%
Tamil Nadu	77	61	25.7%	287	278	3.3%
North India	27	48	-44.0%	128	270	-52.6%
	2,047	1,662	23.2%	7,638	6,412	19.1%

- Strong growth continues at several existing and new centers in Q4-FY18
 - Gulbarga: +37.2% y-o-y
 - Chennai (KMC): +36.1% y-o-y
 - Vizag: +32.3% y-o-y
- Maharashtra region showing momentum in scale-up across centers
- Completed consolidation of partner's cancer business in Andhra (Vijayawada)
- New centers contributed Revenue of INR 434 Mn in Q4-FY18
- Revenue from existing HCG centers, excluding centers being restructured, grew 12.5% in Q4-FY18 on y-o-y basis

Table of Contents





HCG Centers: FY18 Operating Metrics



No. of Centers FY18: 22 FY17: 20	Beds FY18: 1,569 FY17: 1,364	Occupied Bed Days FY18: 253,738 FY17: 220,158 +15.3%	<ul style="list-style-type: none">• 15.3% increase in occupied bed days on account of new centers, impacting AOR by 240 bps• ARPOB for existing centers at INR 33,406• 90 beds reduced on account of Kanpur center exit• Continuing reduction in ALOS to 2.39 on account of trend towards day care procedures and changing patient profile• EBITDA margins impacted with scale-up and losses of new centers• Existing centers EBITDA margin improved by 100 bps to 23.0% in FY'18 from 22.0% in FY'17
Avg. Occupancy Rate FY18: 44.5% FY17: 46.9% 240 bps	ALOS (Days) FY18: 2.39 FY17: 2.86	ARPOB (INR / Day) FY18: 30,832 FY17: 29,122 5.9%	
Revenue (INR mn) FY18: 7,638 FY17: 6,412 +19.1%	EBITDA Margin FY18: 18.1% FY17: 19.2% 110 bps		

Notes:

- (1) No. of Centers includes Cancer and Multispecialty hospitals operated under HCG brand and managed by HCG
- (2) Number of beds in operation as at the last day of the period
- (3) Occupied Bed Days calculated based on mid-day census
- (4) Average Occupancy Rate ("AOR") calculated as Occupied Bed Days divided by available bed days in the period
- (5) Average Revenue per Occupied Bed ("ARPOB") calculated as Revenue (gross for the hospital) divided by Occupied Bed Days
- (6) Average Length of Stay ("ALOS") calculated as Occupied Bed Days divided by number of admissions (including day care admissions)
- (7) EBITDA margin before corporate expenses



HCG Centers: FY18 Regional Highlights



Centers	Beds	AOR	ARPOB (INR/Day)	Revenue (INR MN)	EBITDA (%)
Karnataka					
7	632	44.7%	34.1K	3,247	24.4%
		↑+10.3%(1)	↑+3.7%	↑+12.0%	
Gujarat					
4	304	57.2 %	35.0K	2,220	14.1%
		↑+9.9%(1)	↑+8.9%	↑+19.7%	
Maharashtra					
3	261	41.3%	23.1K	672	6.7%
		N.A.	N.A.	↑+175.0%	
East India					
2	165	67.0%	14.5K	587	25.5%
		↑+0.9%(1)	↑+18.4%	↑+19.5%	

Notes:

- (1) Increase / (Decrease) in Occupied Bed Days
- (2) Growth numbers are year-on-year basis
- (3) EBITDA before corporate expenses

- COE FY18 ARPOB of INR 46.5k, 11.5%+ (y-o-y)
- FY18 ROCE improved from 20.4% to 22.5%
- Continuing drive towards improving quality of business – patient and service mix

- Baroda cancer center and Bhavnagar multi-specialty continue strong ramp-up
- EBITDA margin of existing centers at 18.0% for FY18



- Region showing strong ramp-up and volume growth
- Leadership in radio-surgery segment

- Improved procedure mix and efficiencies in operations leading to optimal occupancy
- Strong growth across both centers in the region

- New centers
- Existing centers




Milann: Expansion on Track



	FY18	FY17	Growth
New Registrations	5,083	4,273	19.0%
IVF Cycles	2,178	1,823	19.5%
Revenue (INR Mn)	669	590	13.5%

- Milann – Ranked #1 nationally for the second consecutive year by the Times of India “All India Fertility & IVF Ranking Survey 2017”
- Planned new center in Whitefield towards continuing leadership in attractive Bangalore market
- Clinical trials and outreach model showing good potential



(1) Centers in operation prior to April 1, 2015, i.e. Shivananda, JP Nagar, and Indiranagar.

Table of Contents





Capital Expenditure and Net Debt



Capital Expenditure

INR Million

	Q4-FY18	FY18	FY17
HCG Centres			
Existing Centres	117	444	260
Expansions	110	220	381
New Centres	651	2,116	1,336
	877	2,780	1,976
Milann Centres			
Existing Centres	-	8	21
New Centres	35	86	98
	35	93	119
Total Capex	912	2,873	2,095

1. Includes Security Deposit for New Centers of INR 58 mn in Q4-FY18, INR 139 mn in FY18 and INR 159 mn in FY17.
2. Capex includes investment for Kanpur center in HCG New Centres.
3. Investment of INR 238 mn in FY18 in HCG Africa not part of Capex.


Net Debt

INR Million

	31-Mar-18	31-Dec-17	31-Mar-17
Net Debt			
Bank Debt ⁽¹⁾	2,374	2,842	1,320
Vendor Finance	1,503	1,797	1,834
Capital Leases	555	476	491
Other Debt	41	45	73
Less: Cash and Equivalents ⁽²⁾	(318)	(772)	(652)
	4,156	4,388	3,066
Debt in New Centres			
Bank Debt	2,261	2,262	885
Vendor Finance	1,261	1,405	1,123
Other Debt	2	2	13
	3,524	3,669	2,021
Net Debt (Excl. New Centres)	632	719	1,045

1. Net of Bank balance held as margin money of INR 183 mn as at 31-Mar-18, INR 327 mn as at 31-Dec-17, and INR 145 mn as at 31-Mar-17. For 31-Mar-18, unamortised portion of processing fees amounting to INR 59 Mn netted off against Bank Debt.
2. Includes investment in mutual funds of INR 43 mn as at 31-Mar-18, INR 40 mn as at 31-Dec-17, and INR 113 mn as at 31-Mar-17 and investment in fixed deposits of INR 47 mn as at 31-Mar-18 and INR 489 mn as at 31-Dec-17.
3. Sale of stake to partner in Kanpur centre completed on 28th March'18 and excluded from Net Debt.

Table of Contents





Project Update



Additional 4 new HCG centers in FY19

Location	Bed Capacity	Project Cost (INR mn)	Start Date
Nashik Phase II, Maharashtra	92	623	Q1-FY19E
Jaipur, Rajasthan	50	410	Q1-FY19E
Kolkata, West Bengal	50	450	Q2-FY19E
Bhavnagar, Gujarat	NA	150	Q2-FY19E
South Mumbai, Maharashtra	32	430	Q3-FY19E

1 new Milann centers launched during FY2018 1 new Milann centers planned for next quarter

Location	Start Date
Delhi	Q1-FY17
Chandigarh	Q3-FY17
Mumbai	Q4-FY17
Ahmedabad	Q4-FY18
Whitefield (Bangalore)	Q1-FY19E





For updates and specific queries, please visit www.hcgel.com
or feel free to contact investors@hcgoncology.com

© 2018 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademarks of HealthCare Global Enterprises Limited

In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.